As of June 30, 2026, Alpha Tau Medical Ltd. carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.16B |
| Enterprise Value | 1.08B |
Alpha Tau Medical Ltd.'s next confirmed earnings release is scheduled for November 24, 2026.
| Earnings Date | 11/24/2026 |
As of June 30, 2026, Alpha Tau Medical Ltd. has 92.33M shares outstanding.
| Shares Outstanding | 92.33M |
These figures are as of June 30, 2026.
| PB Ratio | 26.37 |
| P/TBV Ratio | 26.37 |
As of June 30, 2026, Alpha Tau Medical Ltd. maintains a current ratio of 11.09, meaning it holds 11.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.09 |
| Quick Ratio | 10.66 |
| Debt / Equity | 34.39 |
| Debt / EBITDA | -0.30 |
Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd. posted a negative return on equity (ROE) of -141.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -75.51, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 112.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -141.68 |
| Return on Assets (ROA) | -75.51 |
| Employee Count | 112.00 |
Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd. recorded 175,000.00 in income tax expense. The company reported a pretax loss of -92.40M and -92.57M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 175,000.00 |
As of the close on November 16, 2026, Alpha Tau Medical Ltd.'s stock has gained approximately 222.29% over the past 52 weeks. The 50-day moving average sits at 14.00, while the 200-day moving average is 10.95.
| 52-Week Price Change | 222.29% |
| 50-Day Moving Average | 14.00 |
| 200-Day Moving Average | 10.95 |
Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd. generated - - in revenue and converted that into -92.57M in net income, yielding earnings per share of -1.05. EBITDA reached -50.43M, while operating income came in at -50.43M.
| Operating Income | -50.43M |
| Pretax Income | -92.40M |
| Net Income | -92.57M |
| EBITDA | -50.43M |
| EBIT | -50.43M |
| Earnings Per Share (EPS) | -1.05 |
As of June 30, 2026, Alpha Tau Medical Ltd. holds 100.64M in cash and equivalents against 15.15M in total debt, resulting in a net debt position of -16.19M. Total book value stands at 44.06M, with working capital of 97.20M providing operational flexibility.
| Cash & Cash Equivalents | 100.64M |
| Total Debt | 15.15M |
| Net Debt | -16.19M |
| Equity (Book Value) | 44.06M |
| Book Value Per Share | 0.48 |
| Working Capital | 97.20M |
As of June 30, 2026, Alpha Tau Medical Ltd. has an Altman Z-Score of 4.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.66 |
Already premium?